Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

17.2%

5 terminated/withdrawn out of 29 trials

Success Rate

81.5%

-5.0% vs industry average

Late-Stage Pipeline

69%

20 trials in Phase 3/4

Results Transparency

14%

3 of 22 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3

16(55.2%)

Phase 2

7(24.1%)

Phase 4

4(13.8%)

Phase 1

1(3.4%)

N/A

1(3.4%)

29Total

Phase 3(16)

Phase 2(7)

Phase 4(4)

Phase 1(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (29)

Showing 20 of 29 trials

NCT04724668Not ApplicableCompleted

The Role of the Circadian System in Binge Eating Disorder

Role: collaborator

NCT04235686Phase 2Completed

8 Week Multi-site Study of MYDAYIS® for Bipolar Depression

Role: collaborator

NCT01172652Phase 4Completed

Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder(GAD)

Role: collaborator

NCT03158805Phase 2Completed

Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)

Role: lead

NCT03433339Phase 1Completed

Spinal Cord Stimulation for the Treatment of Major Depressive Disorder

Role: collaborator

NCT04602936Phase 4Unknown

Solriamfetol in Binge Eating Disorder

Role: lead

NCT02659475Phase 2Completed

Phentermine/Topiramate Extended Release in Binge Eating Disorder (BED)

Role: lead

NCT01090713Phase 3Completed

Efficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder

Role: lead

NCT02659488Phase 2Unknown

Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects

Role: lead

NCT01093963Phase 3Terminated

Efficacy Study of Lisdexamfetamine to Treat Bipolar Depression

Role: lead

NCT01010789Phase 3Completed

Armodafinil in Binge Eating Disorder (BED)

Role: lead

NCT01131559Phase 3Terminated

Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression

Role: lead

NCT01033149Phase 3Terminated

N-acetylcysteine in the Treatment of Bulimia Nervosa

Role: lead

NCT01131572Phase 2Terminated

N-acetylcysteine in Bulimia Nervosa

Role: lead

NCT00585208Phase 3Terminated

Add-On Ramelteon in Bipolar I Disorder With Clinically Significant Sleep Disturbance

Role: lead

NCT00276965Phase 3Completed

Bipolar II Depression: Lithium, SSRI, or the Combination

Role: lead

NCT00280839Phase 3Completed

Safety and Efficacy Study of Topiramate to Aid in Smoking Cessation

Role: lead

NCT00363376Phase 3Completed

A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain

Role: lead

NCT00438776Phase 3Completed

Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling

Role: lead

NCT00279617Phase 3Completed

Levetiracetam Treatment of Panic Disorder and Lactate-Induced Panic Attacks

Role: lead